Understanding the biology of angiogenesis: review of the most important molecular mechanisms.

Angiogenesis is an important process for forming new blood vessels. It is fundamental in many biological processes including development, reproduction and wound repair. Under these conditions, angiogenesis is a highly regulated process. Numerous inducers of angiogenesis have been identified, including the members of the vascular endothelial growth factor family, angiopoietins, transforming growth factors, platelet-derived growth factor, tumor necrosis factor-alpha, interleukins and members of the fibroblast growth factor family. Vascular endothelial growth factor-A is the most potent pro-angiogenic protein described to date. It induces proliferation, sprouting and tube formation of endothelial cells. Angiogenesis is therefore a putative target for therapy. The potential application of different angiogenesis inhibitors is currently under intense clinical investigation. A better understanding of the biology of angiogenesis may reveal new targets for treating many diseases that are associated with this complex process. In this review, we summarize the most important molecular mechanisms mediating angiogenesis.

[1]  C. Betsholtz.  Insight into the physiological functions of PDGF through genetic studies in mice. , 2004, Cytokine & growth factor reviews.

[2]  David J. Anderson,et al.  Molecular Distinction and Angiogenic Interaction between Embryonic Arteries and Veins Revealed by ephrin-B2 and Its Receptor Eph-B4 , 1998, Cell.

[3]  S. Weiss,et al.  Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins , 1998, Cell.

[4]  I. Herman,et al.  Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.

[5]  V. Terranova,et al.  Human endothelial cells are chemotactic to endothelial cell growth factor and heparin , 1985, The Journal of cell biology.

[6]  N. Hayward,et al.  Analysis of the promoter region of the human VEGF-related factor gene. , 1997, Biochemical and biophysical research communications.

[7]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[8]  Hiroyuki Aburatani,et al.  Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor‐β in human umbilical vein endothelial cells , 2002, Journal of cellular physiology.

[9]  A. Nash,et al.  The biology of vascular endothelial growth factor-B (VEGF-B). , 2006, Pulmonary pharmacology & therapeutics.

[10]  P. Dell’Era,et al.  Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. , 1991, Cell regulation.

[11]  S. Nicosia,et al.  Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. , 1994, The American journal of pathology.

[12]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[13]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[14]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[15]  P. Vaupel,et al.  Purified monocyte-derived angiogenic substance (angiotropin) induces controlled angiogenesis associated with regulated tissue proliferation in rabbit skin. , 1988, The Journal of clinical investigation.

[16]  Nan Tang,et al.  Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis , 2004 .

[17]  E. Skrzypczak‐Jankun,et al.  Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. , 2004, Oncology Report.

[18]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[19]  G. Neufeld,et al.  Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. , 1993, The Journal of clinical investigation.

[20]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[21]  J. Rossant,et al.  The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. , 1995, The EMBO journal.

[22]  B. Gálvez,et al.  MT1-MMP: Universal or particular player in angiogenesis? , 2006, Cancer and Metastasis Reviews.

[23]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[24]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[25]  J. Mulliken,et al.  The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. , 1999, Journal of cell science.

[26]  D. Rifkin,et al.  Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.

[27]  A. Levy,et al.  Hypoxic Stabilization of Vascular Endothelial Growth Factor mRNA by the RNA-binding Protein HuR* , 1998, The Journal of Biological Chemistry.

[28]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[29]  MS Pepper,et al.  Extracellular Proteolysis and Angiogenesis , 2001, Thrombosis and Haemostasis.

[30]  H. Augustin,et al.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF‐E, mediates angiogenesis via signalling through VEGFR‐2 (KDR) but not VEGFR‐1 (Flt‐1) receptor tyrosine kinases , 1999, The EMBO journal.

[31]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[32]  R. Lobb,et al.  Induction of angiogenesis by bovine brain derived class 1 heparin-binding growth factor. , 1985, Biochemistry.

[33]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[34]  R. W. Rauser,et al.  Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Holger Gerhardt,et al.  Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis , 2001, The Journal of cell biology.

[36]  B. Lévy,et al.  Vascular Endothelial Growth Factor‐B Promotes In Vivo Angiogenesis , 2003, Circulation research.

[37]  Nobuyuki Itoh,et al.  Fibroblast growth factors , 2001, Genome Biology.

[38]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[39]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[41]  L. Claesson‐Welsh,et al.  FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. , 2001, Trends in pharmacological sciences.

[42]  R. Hynes,et al.  Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. , 1999, The Journal of clinical investigation.

[43]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.

[44]  Urban Deutsch,et al.  Angiopoietin-1 induces sprouting angiogenesis in vitro , 1998, Current Biology.

[45]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[46]  S. Kumar,et al.  Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. , 2003, International journal of oncology.

[47]  P. Carmeliet,et al.  Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis , 1999, Cell.

[48]  M. Gassmann,et al.  Defective Brain Development in Mice Lacking the Hif-1α Gene in Neural Cells , 2003, Molecular and Cellular Biology.

[49]  D. Gospodarowicz,et al.  Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Granger,et al.  VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. , 1998, American journal of physiology. Heart and circulatory physiology.

[51]  M. Shibuya,et al.  A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain* , 1998, The Journal of Biological Chemistry.

[52]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[53]  R. Langer,et al.  Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. , 1983, Science.

[54]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[55]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[56]  F. Balkwill,et al.  Hypoxia down‐regulates MCP‐1 expression: implications for macrophage distribution in tumors , 1998, Journal of leukocyte biology.

[57]  T. E. Fitzpatrick,et al.  Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. , 1998, Blood.

[58]  C. Heldin,et al.  Platelet-derived growth factor is angiogenic in vivo. , 1992, Growth factors.

[59]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[60]  M. Kurabayashi,et al.  Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[61]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[62]  B. Meyrick,et al.  Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. , 2006, American journal of physiology. Heart and circulatory physiology.

[63]  A. Mercer,et al.  Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus , 1994, Journal of virology.

[64]  P. Carmeliet,et al.  Transgenic mouse models in angiogenesis and cardiovascular disease , 2000, The Journal of pathology.

[65]  R. Nicosia,et al.  Regulation of Vascular Growth and Regression by Matrix Metalloproteinases in the Rat Aorta Model of Angiogenesis , 2000, Laboratory Investigation.

[66]  P. Carmeliet,et al.  VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[67]  M. Boes,et al.  The effects of platelet-derived growth factor in cultured microvessel endothelial cells. , 1989, Endocrinology.

[68]  M. Corada,et al.  Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). , 1996, The Journal of clinical investigation.

[69]  Thomas N. Sato,et al.  Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.

[70]  Stephen J. Weiss,et al.  MT1-MMP–dependent neovessel formation within the confines of the three-dimensional extracellular matrix , 2004, The Journal of cell biology.

[71]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  M. Corada,et al.  Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. , 1998, Journal of cell science.

[73]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[74]  Juan P. Albar,et al.  Membrane Type 1-Matrix Metalloproteinase Is Activated during Migration of Human Endothelial Cells and Modulates Endothelial Motility and Matrix Remodeling* , 2001, The Journal of Biological Chemistry.

[75]  W. Aird,et al.  PDGF mediates cardiac microvascular communication. , 1998, The Journal of clinical investigation.

[76]  Pieter Koolwijk,et al.  Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. , 2004, The Journal of clinical endocrinology and metabolism.

[77]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[78]  M. Porteous,et al.  A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. , 2003, Human molecular genetics.

[79]  J. Ward,et al.  MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.

[80]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[81]  A. Harris,et al.  Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‐Lindau gene and hypoxia , 2002, The Journal of pathology.

[82]  W. Wood,et al.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[83]  C. Eng,et al.  From developmental disorder to heritable cancer: it's all in the BMP/TGF-β family , 2003, Nature Reviews Genetics.

[84]  A. Sica,et al.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter , 1995, The Journal of experimental medicine.

[85]  V. Devita,et al.  Biologic Therapy of Cancer , 1992 .

[86]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[87]  I. Morita,et al.  Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. , 1994, Biological & pharmaceutical bulletin.

[88]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[89]  J. L. Bethune,et al.  Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. , 1985, Biochemistry.

[90]  E. Sage,et al.  PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors , 1994, The Journal of cell biology.

[91]  L. Forman,et al.  Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. , 1998, The Journal of laboratory and clinical medicine.

[92]  V. Hombach,et al.  Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. , 1996, Circulation.

[93]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[94]  J. Tuxhorn,et al.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. , 2002, Cancer research.

[95]  M. Greenblatt,et al.  Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. , 1968, Journal of the National Cancer Institute.

[96]  G. Martiny-Baron,et al.  Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. , 1997, Cancer research.

[97]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[98]  K. Alitalo,et al.  Vascular endothelial growth factor (VEGF)‐C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity , 1998, Journal of cellular physiology.

[99]  A. Albini,et al.  c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[100]  M. Goumans,et al.  Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. , 2003, Trends in cardiovascular medicine.

[101]  María Yáñez-Mó,et al.  ECM regulates MT1-MMP localization with β1 or αvβ3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells , 2002, The Journal of cell biology.

[102]  D. Rifkin,et al.  Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. , 2000, Advances in cancer research.

[103]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[104]  C. Betsholtz,et al.  Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. , 2003, The Journal of clinical investigation.

[105]  C. Mummery,et al.  Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. , 2003, Cardiovascular research.

[106]  J. Folkman,et al.  Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border , 1998, Cell.

[107]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[108]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[109]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[110]  J. Rossant,et al.  tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. , 1992, Oncogene.

[111]  G. Kay,et al.  Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. , 2003, Arthritis and rheumatism.

[112]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[113]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[114]  M. Knoth,et al.  Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. , 1968, Journal of the National Cancer Institute.

[115]  M. Goldberg,et al.  Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. , 1994, The Journal of biological chemistry.

[116]  D. Yamashiro,et al.  Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[117]  E. Small,et al.  Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  D. Gingras,et al.  Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. , 2004, Blood.

[119]  VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.

[120]  P. Einat,et al.  Translation of Vascular Endothelial Growth Factor mRNA by Internal Ribosome Entry: Implications for Translation under Hypoxia , 1998, Molecular and Cellular Biology.

[121]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[122]  S. Kourembanas,et al.  Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. , 1995, Circulation research.

[123]  V. V. van Hinsbergh,et al.  Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. , 2000, Blood.

[124]  J. Alexander,et al.  Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins* , 1998, The Journal of Biological Chemistry.

[125]  S. Mandriota,et al.  Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. , 2000, The American journal of pathology.

[126]  G. Semenza,et al.  Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. , 2005, Blood.

[127]  K. Tryggvason,et al.  Distinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation. , 2005, Developmental biology.

[128]  H. Phillips,et al.  Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. , 1993, Endocrinology.

[129]  J. Partanen,et al.  The mouse tie receptor tyrosine kinase gene: expression during embryonic angiogenesis. , 1994, Oncogene.